Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study - The Lancet Haematology
Amyloidosis | Saint Luke's Health System
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis | NEJM
Our research | Gareth Morgan
Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation | eLife
AL Amyloidosis | Amyloidosis Foundation
What do I need to know about immunoglobulin light chain (AL) amyloidosis? - ScienceDirect
AL Amyloidosis (Primary Amyloidosis): Symptoms, Treatment & What it Is
SciELO - Brasil - Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies Serum free light chain assays not total light chain
Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response | Heart
IJMS | Free Full-Text | Noninvasive Diagnostics of Renal Amyloidosis: Current State and Perspectives
A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin λ6 Light Chain Promotes Pathologic Amyloid Formation - ScienceDirect
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021 | Blood Cancer Journal
Molecules that prevent protein misfolding point to new type of therapy for AL amyloidosis | Scripps Research
Cardiac Amyloidosis Program
Frontiers | Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Mutations in Specific Structural Regions of Immunoglobulin Light Chains Are Associated with Free Light Chain Levels in Patients with AL Amyloidosis | PLOS ONE
Update on treatment of light chain amyloidosis | Haematologica
Amyloid formation by antibody light chains. In AL amyloidosis, LCs,... | Download Scientific Diagram